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Primary	hypomagnesemia	is	a	heterogeneous	group	of	disorders	characterized	by	renal	or	intestinal	mag-
nesium	(Mg2+)	wasting,	resulting	in	tetany,	cardiac	arrhythmias,	and	seizures.	The	kidney	plays	an	essential	
role	in	maintaining	blood	Mg2+	levels,	with	a	prominent	function	for	the	Mg2+-transporting	channel	transient	
receptor	potential	cation	channel,	subfamily	M,	member	6	(TRPM6)	in	the	distal	convoluted	tubule	(DCT).	In	
the	DCT,	Mg2+	reabsorption	is	an	active	transport	process	primarily	driven	by	the	negative	potential	across	the	
luminal	membrane.	Here,	we	studied	a	family	with	isolated	autosomal	dominant	hypomagnesemia	and	used	
a	positional	cloning	approach	to	identify	an	N255D	mutation	in	KCNA1,	a	gene	encoding	the	voltage-gated	
potassium	(K+)	channel	Kv1.1.	Kv1.1	was	found	to	be	expressed	in	the	kidney,	where	it	colocalized	with	TRPM6	
along	the	luminal	membrane	of	the	DCT.	Upon	overexpression	in	a	human	kidney	cell	line,	patch	clamp	ana-
lysis	revealed	that	the	KCNA1	N255D	mutation	resulted	in	a	nonfunctional	channel,	with	a	dominant	negative	
effect	on	wild-type	Kv1.1	channel	function.	These	data	suggest	that	Kv1.1	is	a	renal	K+	channel	that	establishes	
a	favorable	luminal	membrane	potential	in	DCT	cells	to	control	TRPM6-mediated	Mg2+	reabsorption.
Introduction
Occurrence of hypomagnesemia (serum Mg2+ levels below 0.70 
mmol/l) in the general population has been estimated to be 
around 2%, while hospitalized patients are more prone to develop 
hypomagnesemia (12%) (1). Recent studies of intensive care 
patients have even estimated frequencies as high as 60% (2). The 
blood Mg2+ concentration depends on the renal Mg2+ excretion in 
response to altered uptake by the intestine. Hence, the kidney is 
essential for the maintenance of the Mg2+ balance (3). The major-
ity of filtered Mg2+ is reabsorbed along the proximal tubule and 
the thick ascending limb of Henle’s loop via a passive paracellular 
pathway (4). However, fine-tuning of Mg2+ excretion occurs in the 
distal convoluted tubule (DCT) in an active transcellular fashion 
initiated by the Mg2+-permeable transient receptor potential cat-
ion channel, subfamily M, member 6 (TRPM6) (5, 6). Since the 
extra- and intracellular Mg2+ concentrations are both in the mil-
limolar range, it has been hypothesized that the membrane poten-
tial across the luminal membrane acts as the primary driving force 
for Mg2+ entry via TRPM6 (6, 7). Previously, genetic studies in fam-
ilies with hereditary renal Mg2+ wasting syndromes revealed several 
new genes involved in Mg2+ homeostasis, including tight junction 
proteins claudin 16 and 19 (8, 9), the thiazide-sensitive sodium 
chloride cotransporter (NCC) (10), the γ-subunit of the Na+/K+-
ATPase (FXYD2) (11), TRPM6 (12, 13), and the recently discovered 
magnesiotropic hormone EGF (14). Despite these discoveries, our 
knowledge of renal Mg2+ handling remains far from complete.
In this study, we screened a Brazilian family with isolated auto-
somal dominant hypomagnesemia and identified a missense 
mutation in KCNA1, resulting in nonfunctionality of the encoded 
voltage-gated potassium channel Kv1.1.
Results
A heterozygous KCNA1 A763G mutation is causative for hypomagnesemia. 
Here, we identified a large Brazilian family (46 family members, 
of which 21 are affected) with autosomal dominant hypomagne-
semia (Figure 1A). Affected individuals showed low serum Mg2+ 
levels (<0.40 mmol/l; normal range, 0.70–0.95 mmol/l), while their 
urinary Mg2+ excretion was normal, suggesting impaired tubular 
Mg2+ reabsorption. The phenotype of the proband (IV-3, Figure 
1A) starting from infancy consists of recurrent muscle cramps, 
tetanic episodes, tremor, and muscle weakness, especially in distal 
limbs. An SNP-based linkage analysis identified a 14.3-cM locus 
on the short arm of chromosome 12 (Figure 1B), which was subse-
quently narrowed down by fine mapping with microsatellite mark-
ers to an 11.6-cM region containing 31 genes between the mark-
ers D12S1626 and D12S1623 (maximum multipoint lod score, 
3.0) (Figure 1B and Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI36948DS1). 
Other genes previously associated with hypomagnesemia are 
located outside this critical region and therefore were excluded 
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as candidate genes in our family. From the identified locus, we 
sequenced KCNA1 and identified a heterozygous mutation, A763G 
(Figure 1C), in the affected individual III-1 (Figure 1A) that coseg-
regates with the disorder and was absent in 100 control chromo-
somes (data not shown). The identified mutation in KCNA1, which 
encodes the Shaker-related voltage-gated K+ channel Kv1.1, causes 
substitution of the highly conserved asparagine at position 255 
for an aspartic acid (N255D) (Figure 1D). The predicted amino 
acid topology of Kv channels shows 6 transmembrane-spanning 
α-helical segments (i.e., S1–S6), with the S4 segment acting as the 
voltage sensor and a hydrophobic pore region between S5 and S6 
(Figure 1E) (15). The newly identified N255D mutation is posi-
tioned in the third transmembrane segment (S3) close to the volt-
age sensor (Figure 1E).
Localization of Kv1.1 in the DCT of the kidney. So far, all proteins 
implicated in familial hypomagnesemia have been shown to be 
expressed in kidney, underlining the pivotal role of this organ in 
body Mg2+ homeostasis. To study the (sub)cellular localization 
of Kv1.1 in kidney, we used a rabbit polyclonal antibody raised 
against the Kv1.1 channel. Immunopositive staining was observed 
along the luminal membrane of distinct tubules present in the 
superficial cortex of the mouse kidney (Figure 2). Using serial 
kidney sections, we demonstrated that Kv1.1 colocalizes with the 
epithelial Mg2+ channel TRPM6 in DCT (Figure 2A). To confirm 
this localization, we costained kidney sections for Kv1.1 and cal-
bindin D28K and found a partial overlap in Kv1.1 and calbindin 
D28K expression (Figure 2B). This pattern can be explained by ear-
lier observations that calbindin D28K is expressed not only in the 
DCT but also in connecting tubule (CNT) (16). Therefore, these 
data confirm that Kv1.1 is localized primarily in the DCT. Indeed, 
costaining between Kv1.1 and aquaporin-2 (AQP2), a marker for 
CNT and the collecting duct, was not observed (Figure 2C). These 
findings support the restricted localization of Kv1.1 in the Mg2+-
transporting DCT segment of the kidney.
Figure 1
Heterozygous KCNA1 A763G mutation causes isolated hypomagnesemia. (A) Pedigree with 5 generations (I–V) of a Brazilian family with auto-
somal dominant hypomagnesemia. Affected family members are indicated in black; males and females are indicated by squares and circles, 
respectively. A diagonal line indicates that the individual is deceased. Numbers in red indicate individuals included in the Sequence Tagged Site 
(STS) mapping. (B) 10K SNP array–based haplotyping analysis was performed that showed linkage to a 14.3-cM region between SNP rs717596 
and rs252028 on the short arm of chromosome 12. This region was confirmed and narrowed down with STS markers to a 11.6-cM region 
between markers D12S1626 and D12S1623 containing 31 genes, including KCNA1. (C) KCNA1 encodes the voltage-gated potassium channel 
Kv1.1. Mutation analysis of KCNA1 revealed a heterozygous A763G missense mutation in affected individual III-1 that results in a N255D amino 
acid substitution (underlined). (D) Multiple alignment analysis shows conservation of the N255 amino acid (red bar) among species and Kv1 
family members. Mutated amino acids in other families with the Kv1.1 genotype are indicated by dark blue dots (17, 19, 21, 22). Blue and black 
letters represent conserved and nonconserved amino acids, respectively. (E) Schematic representation of the Kv1.1 channel, which consists of 
a voltage sensor in transmembrane segment S4 and a pore-forming region (S5 and S6). Localization of the newly identified N255D mutation is 
denoted by the red dot, while other nearby mutations are indicated by dark blue dots.
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Kv1.1 N255D results in nonfunctional channels with dominant nega-
tive effect on wild-type channel function. To determine the effect of the 
Kv1.1 N255D mutation on channel activity, HEK293 cells were 
mock transfected or were transiently transfected with wild-type 
Kv1.1 and/or Kv1.1 N255D. Using the whole-cell patch clamp 
technique, we measured outward K+ currents by dialyzing the cells 
with a pipette solution containing 140 mM K+. Cells expressing 
wild-type Kv1.1 channels produced typical delayed rectifying cur-
rents, while Kv1.1 N255D–expressing HEK293 cells showed small 
currents similar to those of mock plasmid–expressing cells (Figure 
3, A and B). Considering the autosomal dominant inheritance in 
our family, we investigated a potential dominant negative effect by 
cotransfection of equal amounts of plasmid DNA encoding wild-
type Kv1.1, Kv1.1 N255D, or mock plasmid in HEK293 cells. The 
K+ current amplitude in HEK293 cells coexpressing wild-type Kv1.1 
and Kv1.1 N255D was significantly reduced compared with that 
in cells expressing wild-type Kv1.1 alone or coexpressing wild-type 
Kv1.1 and mock plasmid (P < 0.05) (Figure 3C). Next, the influ-
ence of Kv1.1 N255D expression on the amount of Kv1.1 channels 
at the plasma membrane was examined by cell surface biotinyl-
ation experiments. As shown in Figure 3D, coexpression of wild-
type Kv1.1 and Kv1.1 N255D in HEK293 cells did not affect the 
plasma membrane localization of Kv1.1 channels. Of note, Kv1.1 
was equally expressed in all conditions as analyzed in the total cell 
lysates (Figure 3D, bottom panel). As Kv1.1 channels are composed 
of 4 subunits, this result suggests that similar amounts of both 
homotetrameric channels of wild-type Kv1.1 or Kv1.1 N255D, and 
heterotetrameric channels composed of wild-type Kv1.1 with Kv1.1 
N255D are located at the plasma membrane.
Kv1.1 regulates TRPM6 Mg2+ influx by setting the membrane potential. 
Since Kv1.1 and TRPM6 are present in the same nephron segment, 
we investigated by which mechanism Kv1.1 controls Mg2+ influx 
through TRPM6. We studied the potential direct effect of Kv1.1 on 
TRPM6 activity by patch clamp analysis. To this end, TRPM6 (1.0 
μg) was cotransfected with mock plasmid (0.1 μg), wild-type Kv1.1 
(0.1 μg), or Kv1.1 N255D (0.1 μg) in HEK293 cells. The TRPM6-
mediated Na+ currents were virtually identical in the 3 experimen-
tal conditions (Figure 3E). Subsequently, the current clamp mode 
of the patch clamp technique was used to measure the membrane 
potential of HEK293 cells expressing wild-type Kv1.1 or Kv1.1 
N255D. A significant hyperpolarization (P < 0.05) was observed 
in wild-type Kv1.1-expressing HEK293 cells (–39 ± 3 mV, n = 9) 
compared with mock plasmid– or Kv1.1 N255D–expressing cells 
(–3 ± 1 mV, n = 7, and –8 ± 2 mV, n = 7, respectively). Dendrotoxin K 
(DTX-K, 10 nM), a specific Kv1.1 channel blocker, significantly 
depolarized the membrane potential in wild-type Kv1.1-express-
ing cells (from –39 ± 3 mV to –14 ± 2 mV, n = 8, P < 0.05) (Figure 
3F). The membrane potential of mock plasmid– or Kv1.1 N255D–
expressing cells was not affected by DTX-K application (Figure 3F). 
Furthermore, cotransfection of wild-type Kv1.1 and Kv1.1 N255D 
resulted in an intermediate hyperpolarization compared with the 
cells expressing only wild-type Kv1.1 (–23 ± 1 mV vs. –39 ± 3 mV, 
respectively, n = 15, P < 0.05). These results suggest that compared 
with the normal Kv1.1 channel, the Kv1.1 N255D channel dimin-
ishes negative membrane potential.
Discussion
In this study, we identified a large Brazilian family with autoso-
mal dominant hypomagnesemia. Affected individuals showed 
low serum Mg2+ levels, while serum K+ and Ca2+ levels and urinary 
Ca2+ excretion were not affected, which is distinct from previ-
ously described forms of inherited hypomagnesemia. For exam-
ple, members of families bearing a mutation in claudin 16 and 
claudin 19 (familial hypomagnesemia with hypercalciuria and 
Figure 2
Immunohistochemical analysis of Kv1.1 in kidney. (A) Staining for Kv1.1 (green) and TRPM6 (red) of mouse serial kidney sections (right panels: 
overview of a cortical region; left panels: magnified images of immunopositive tubules). The asterisks indicate the same distal tubules on serial 
sections intensively stained for Kv1.1 and TRPM6. (B) Mouse kidney sections were costained for Kv1.1 (green) and calbindin D28K (red) (lower 
panels: immunopositive tubules; upper panel: merged differential interference contrast [DIC] image). (C) Costaining of Kv1.1 (green) and AQP2 
(red) in mouse kidney sections (lower panels: immunopositive tubules; upper panel: merged DIC image). G, glomerulus; 28K, calbindin D28K. 
Scale bars: 50 μm (A, left panels), 80 μm (A, right panels; C, bottom panels), 20 μm (B, top panel), 40 μm (B, bottom panels; C, top panel).
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nephrocalcinosis; OMIM 248250 and 248190) are hypercalciuric, 
while mutations in FXYD2 (isolated dominant hypomagnesemia 
[IDH]; OMIM 154020) and TRPM6 (hypomagnesemia with sec-
ondary hypocalcemia; OMIM 602014) result in hypocalciuria and 
hypocalcemia, respectively. Furthermore, patients with Gitelman 
syndrome (OMIM 263800), caused by mutations in NCC, suffer 
from hypomagnesemia, hypocalciuria, and hypokalemia. The phe-
notype in the proband starting from infancy consists of recurrent 
muscle cramps, tetanic episodes, tremor, and muscle weakness, 
especially in distal limbs. Serum electrolyte levels were measured 
during severe attacks of cramps and tetany in 2 affected family 
members (proband V-3; V-2), with serum Mg2+ levels of 0.37 and 
0.25 mmol/l, respectively, while serum Ca2+ and K+ concentrations 
were normal. As a result, all affected family members received a 
daily dose of magnesium chloride. Importantly, the proband was 
hospitalized during the course of this study because of a sudden 
episode of facial myokymia, tremor, severe muscle spasms, muscu-
lar pain, cramps, muscular weakness, and tetanic contraction epi-
sodes, all of which improved shortly after intravenous magnesium 
treatment. This observation further confirmed that the observed 
symptoms are a consequence of the low serum Mg2+ levels.
By use of a positional cloning approach, we revealed a hetero-
zygous mutation in KCNA1, encoding the voltage-gate potassium 
channel Kv1.1, by which the asparagine at amino acid position 
255 was converted into an aspartic acid (N255D). Remarkably, 
the Kv1.1 N255D genotype causes hypomagnesemia, whereas 
Figure 3
Electrophysiological analysis of HEK293 cells transfected with mock plasmid, wild-type Kv1.1 (Kv1.1 WT), or Kv1.1 N255D. (A) Representative 
original traces of outward K+ currents of cells transfected with mock plasmid, Kv1.1 WT, Kv1.1 N255D, or Kv1.1 WT and mock plasmid elicited 
by voltage steps from –100 to +50 mV in 10-mV increments, applied from a holding potential of –80 mV, every 10 seconds. (B) The I-V relation-
ships of cells transfected with mock plasmid (circles, n = 5), Kv1.1 WT (squares, n = 11), Kv1.1 N255D (triangles, n = 10), and Kv1.1 WT and 
mock plasmid (diamonds, n = 9). (C) Histogram presenting averaged current densities at +50 mV of cells transfected with mock plasmid (n = 5), 
Kv1.1 WT (n = 11), Kv1.1 WT and mock plasmid (n = 9), Kv1.1 WT and Kv1.1 N255D (n = 9), and Kv1.1 N255D (n = 10). *P < 0.05, compared 
with mock; #P < 0.05, compared with Kv1.1 WT. (D) Cell surface biotinylation of HEK293 cells transfected with mock plasmid, Kv1.1 WT, Kv1.1 
WT and mock plasmid, Kv1.1 WT and Kv1.1 N255D, and Kv1.1 N255D. Kv1.1 expression was analyzed by immunoblotting for plasma mem-
brane fraction (PM) and input from the total cell lysates (IP). Representative immunoblot of 4 independent experiments is shown. (E) Histogram 
presenting averaged current densities at +80 mV after 200 seconds of cells cotransfected with TRPM6 and mock plasmid (n = 26), TRPM6 and 
Kv1.1 WT (n = 26), and TRPM6 and Kv1.1 N255D (n = 25). (F) Membrane potential of cells transfected with mock plasmid, Kv1.1 WT, and Kv1.1 
N255D upon acute application of DTX-K (10 nM), measured in current clamp mode of whole-cell patch clamp configuration. Representative 
recordings of 8 independent experiments are shown. The error bars denote SEM.
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mutations in KCNA1 thus far have been shown to result in epi-
sodic ataxia type 1 (EA1). Figure 1, D and E, shows the previously 
identified mutations in close proximity to the N255D mutation 
(17–22). EA1 is a dominant human neurological disorder presum-
ably caused by defective Kv1.1 in the cerebellum. Furthermore, 
abnormal Kv1.1 activity, originating in the distal motor axons, 
results in muscle hyperactivity, indicative for myokymia (23, 24). 
In addition to the classical description of this disorder, phenotypic 
variants include EA1 with partial epilepsy (18, 19), EA1 without 
myokymia (20), and isolated neuromyotonia (19). We also ana-
lyzed the affected members of our Brazilian family for episodic 
ataxia. On a cerebral MRI of the proband, we obtained evidence 
of a slight atrophia of the cerebral vermis (data not shown). Fur-
thermore, electromyographs of some affected members showed 
myokymic discharge, in line with the previously observed mixed 
phenotype (data not shown). Now, we present hypomagnesemia 
as a new phenotypic characteristic associated with a mutation 
in KCNA1. Thus, it would be interesting to perform in the near 
future a large-scale phenotypical characterization of patients with 
identified mutations in the KCNA1 gene, including neurological 
description, serum Mg2+ levels, and functional analysis of the cor-
responding Kv1.1 mutations.
Previously, genetic studies in familial hypomagnesemia revealed 
several new proteins with a predominant expression in kidney, 
underlining its involvement in Mg2+ homeostasis. Our immuno-
histochemical data clearly demonstrated the localization of Kv1.1 
along the luminal membrane of TRPM6-expressing DCT cells, 
consistent with a potential link between Kv1.1-mediated K+ secre-
tion and Mg2+ influx via TRPM6. Therefore, we assessed the role 
of Kv1.1 in controlling Mg2+ influx via TRPM6. Electrophysiologi-
cal analysis of wild-type Kv1.1 and Kv1.1 N255D revealed that the 
mutation results in a nonfunctional Kv1.1 channel. Kv1.1 chan-
nels consist of 4 subunits arranged symmetrically around an aque-
ous pore, forming a so-called tetrameric structure (25, 26). It has 
been shown that Kv1.1 channel subunits can assemble with other 
Kv channel subunits to form heterotetramers (27). Importantly, 
hypomagnesemia in the Brazilian family is inherited in an autoso-
mal dominant manner, and patients with the N255D mutation are 
heterozygous. Expression of both alleles likely results in the for-
mation of heterotetrameric channels composed of wild-type and 
mutated channel subunits, leading to a dominant negative effect 
by the Kv1.1 N255D subunit, as shown in this study. The mutation 
replaces a neutral amino acid (asparagine) with one with an acidic 
side chain (aspartic acid), which may destabilize the secondary or 
tertiary channel structure and thereby channel formation or traf-
ficking. However, we demonstrated that wild-type Kv1.1 channels, 
Kv1.1 N255D channels, and the combination thereof are expressed 
in equal amounts at the plasma membrane.
Considering the striking localization of Kv1.1 in the TRPM6-
expressing DCTs, we investigated a potential direct functional 
effect of Kv1.1 on TRPM6 activity. However, neither wild-type 
Kv1.1 nor Kv1.1 N255D altered the TRPM6-mediated Na+ cur-
rents, and it is therefore unlikely that Kv1.1 directly regulates the 
activity of the Mg2+-permeable channel TRPM6. Mg2+ is actively 
reabsorbed in the DCT. Here, Mg2+ influx through TRPM6 is 
driven by a favorable membrane voltage (6, 7). This membrane 
potential is maintained by a so-far-unidentified apical K+ efflux 
pathway, while the K+ gradient is provided by the basolaterally 
localized Na+/K+-ATPase. Previously, a mutation in the Na+/K+-
ATPase γ-subunit was shown to be the underlying cause of auto-
somal dominant renal Mg2+ wasting and secondary hypocalciuria 
(11). Interestingly, K+ efflux through K+-permeable channels pri-
marily determines the resting membrane potential. Kv channels 
are widely expressed in excitable and nonexcitable cells, where they 
play an essential role in the establishment of the electrical proper-
ties of the cell, instrumental for many processes (28). By use of 
the current clamp mode of the patch clamp technique, we demon-
strated that the plasma membrane is hyperpolarized to a signifi-
cant extent in Kv1.1- compared with mock or Kv1.1 N255D–trans-
fected cells. This effect was reversible by DTX-K, a specific Kv1.1 
channel blocker, confirming the involvement of Kv1.1 in setting 
the negative membrane potential. We now hypothesize that the 
voltage-gated Kv1.1 channel is responsible for the establishment 
of the negative membrane potential across the luminal membrane 
of the DCT cell. The N255D mutation leads to depolarization of 
the luminal membrane, notably diminishing the driving force for 
Mg2+ uptake from the pro-urine (Figure 4).
In conclusion, our study discloses a new direct coupling between 
K+ secretion and active Mg2+ reabsorption, which is highlighted by 
our discovery of the N255D mutation in the KCNA1 gene in auto-
somal dominant hypomagnesemia. The encoded K+ channel Kv1.1 
colocalizes with the Mg2+ influx channel TRPM6 along the luminal 
membrane of DCT, the main site of active renal Mg2+ reabsorption. 
Kv1.1 channels harboring the N255D mutation show near-back-
ground currents, impairing their ability to set a membrane poten-
tial that favors TRPM6-mediated Mg2+ influx. These findings will 
open a new window for other studies on the interrelationship of 
renal K+ and Mg2+ disturbances.
Methods
Subjects. The study was approved by the Clinical Hospital, Parana Federal 
University (Curitiba, Paraná, Brazil), and written informed consent was 
obtained from the subjects. We identified a large family (46 family mem-
Figure 4
Schematic model of the Mg2+-reabsorbing DCT cell in the kidney. Mg2+ 
uptake from the pro-urine via the epithelial Mg2+ channel TRPM6 is 
primarily driven by the negative potential across the luminal mem-
brane. This luminal membrane potential is maintained by an apical 
K+ efflux via Kv1.1 energized by the action of the Na+/K+-ATPase. At 
the basolateral membrane, Mg2+ extrusion to the blood side occurs via 
an unknown mechanism. The identified N255D mutation results in a 
nonfunctional Kv1.1 channel and thereby decreases the driving force 
for Mg2+ influx, thus resulting in renal Mg2+ wasting.
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bers, 21 affected) with autosomal dominant hypomagnesemia (Figure 1A). 
The phenotype in the proband (IV-3) starting from infancy included 
recurrent muscle cramps, tetanic episodes, tremor, and muscle weakness, 
especially in distal limbs. There were no seizures, recurrent urinary tract 
infections, polyuria, polydipsia, or renal stones. At 4 years the patient was 
determined to have significant hypomagnesemia (0.37 mmol/l; normal, 
0.70–0.95 mmol/l). Serum K+ (3.9 mmol/l; normal, 3.5–5.0 mmol/l), Ca2+ 
(2.35 mmol/l; normal, 2.15–2.50 mmol/l), sodium, phosphate, uric acid, 
bicarbonate, urea, creatinine, glucose, bilirubin, aminotransferases, alka-
line phosphate, and lactate dehydrogenase were all normal. Urinary cre-
atinine clearance, urinary Mg2+ excretion (2.8 mmol/24 h; normal 2.1–6.2 
mmol/24 h), and Ca2+ excretion were also normal. The patient received a 
daily dose of magnesium chloride, which improved muscular weakness, 
but slight muscle cramps persisted, particularly after physical activity. 
One of her younger brothers (IV-1, Figure 1A) died in infancy from a 
severe attack of cramps and tetany. At that time, the serum Mg2+ level was 
as low as 0.28 mmol/l. In addition, 18 other family members had shown 
similar clinical manifestations and biochemical features. The proband 
was tested for signs of cerebellar dysfunction and reported having expe-
rienced several periods during which she was not able to walk straight. 
Objective clinical signs of cerebellar dysfunction, including nystagmus, 
multistep or overshoot saccades, dysmetria in the finger-nose test, and 
decomposition of movement of the legs on heel-to-shin test, were absent. 
However, on a cerebral MRI of the proband, we found evidence of slight 
atrophia of the cerebral vermis (data not shown). Furthermore, electro-
myographs of some affected members showed myokymic discharge in line 
with the previously observed mixed phenotype. We collected blood sam-
ples of the family members (both affected and nonaffected; Figure 1A) 
for linkage analysis. Subsequently, DNA was extracted according to stan-
dard protocols. Control genomic DNA samples (n = 100) were provided 
by H. van Bokhoven (Department of Human Genetics, Radboud Univer-
sity Nijmegen Medical Centre).
Genetic linkage analysis. A genome-wide linkage approach was per-
formed for 12 family members selected based on simulations in SLINK 
(29) using the Affymetrix GeneChip Mapping 10K 2.0 Array harboring 
10,204 SNPs. Sample preparation and hybridization were performed 
according to the manufacturer’s protocol (Affymetrix) (30). Briefly, 250 
ng of genomic DNA was digested using 10 U XbaI (Westburg), followed 
by ligation using T4 DNA ligase (Westburg) of universal adaptors to the 
digested products. Primers complementary to the adaptors were used for 
amplification of the digested products. After purification of the prod-
ucts using MinElute plates (QIAGEN), fragmentation was performed on 
20 μg purified PCR product. Fragmented products were end-labeled and 
hybridized to the Affymetrix 10K GeneChip overnight. Hybridized arrays 
were washed and stained using the Fluidics Station 400 (Affymetrix). The 
GeneChip Scanner 3000 was used to scan the hybridized arrays. Auto-
matic SNP calls were generated using GeneChip DNA analysis software 
(GDAS; Affymetrix). SNP calls are AA or BB for homozygous SNPs, AB for 
heterozygous SNPs. When the software was unable to make a call (AA, BB, 
or AB), the SNP was scored as “no call.” Merlin software (www.sph.umich.
edu/csg/abecasis/Merlin/index.html) was used to calculate lod scores. 
Eight microsatellite markers (D12S1626, D12S1725, D12S99, D12S374, 
D12S1623, D12S336, D12S77, and D12S89) were selected to fine-map 
the newly identified hypomagnesemia loci on the short arm of chromo-
some 12 (Human Genome Browser Gateway; http://genome.ucsc.edu/ 
cgi-bin/hgGateway). Marker analysis using fluorescently labeled primers 
was performed according to the protocol for Linkage Mapping Set MD10 
version 2.5 (Applied Biosystems). Reactions for each marker were performed 
separately, with products being pooled into size- and label-specific sets 
before typing. Markers were typed on an ABI 3730 DNA analyzer (Applied 
Biosystems) using GeneMapper 4.0 software (Applied Biosystems). Allele 
binning was performed with the Excel 2000 (Microsoft) macro linkage 
designer developed by van Camp and coworkers (31), and we checked 
Mendelian inheritance of alleles with PedCheck 1.0 software (http:// 
watson.hgen.pitt.edu/register/docs/pedcheck.html) (32). Multipoint lod 
score and haplotype analysis was performed with GeneHunter, version 2.1 
release 5, in the easyLINKAGE software package (33) and Haplopainter 
software (haplopainter.sourceforge.net/html/index.html).
Mutation analysis. From the critical region, we selected the KCNA1 gene 
for mutation analysis, using the UCSC Genome Browser database (http://
genome.ucsc.edu/). DNA amplification reactions were performed in a 
thermal cycler with heated lid (PTC-200; MJ Research). The KCNA1 exon 
sequence and flanking regions were amplified from genomic DNA of indi-
vidual III-1 (Figure 1A) using multiple overlapping primer sets based on 
GenBank accession code BC101733 (Supplemental Table 1). PCR products 
of correct sizes were selected by DNA agarose gel electrophoresis, follow-
ing excision and subsequent purification with GenElute Gel Extraction Kit 
(Sigma-Aldrich) according to the manufacturer’s protocol. The fragments 
were sequenced on both strands by use of the ABI PRISM Big Dye Termi-
nator v2.0 Ready Reaction Cycle Sequencing Kit and the ABI PRISM 3730 
DNA analyzer (Applied Biosystems).
Immunohistochemistry. Immunohistochemistry was performed as previ-
ously described (34). In short, either coimmunohistochemical staining 
or staining of serial sections for Kv1.1 with TRPM6, calbindin D28K, and 
AQP2 was performed on 7-μm sections of fixed frozen mouse kidney sam-
ples. The mouse kidney cryosections were incubated for 16 hours at 4°C 
with the following primary antibodies: rabbit anti-Kv1.1 (1:300) (APC-009; 
Alomone Labs), guinea pig anti-TRPM6 (1:1,000) (6), guinea pig anti-AQP2 
(1:1,000) (provided by P.M.T. Deen, Department of Physiology, Radboud 
University Nijmegen Medical Centre), and mouse anti–calbindin D28K 
(1:750) (35). For detection of calbindin D28K and AQP2, sections were incu-
bated with Alexa Fluor–conjugated secondary antibodies. The Tyramide 
Signal Amplification kit (PerkinElmer) was used after incubation with 
biotin-coated goat anti-rabbit and goat anti–guinea pig secondary anti-
bodies to visualize Kv1.1 and TRPM6, respectively. Images were taken with 
a confocal laser scanning imaging system (FluoView FV1000; Olympus).
DNA constructs. The KCNA1 wild-type and N255D mutant sequences were 
obtained by amplification of genomic DNA from a nonaffected and affected 
family member, respectively, using primers 5′-GCCGAATTCGGCCAC-
CATGACGGTGATGTC-3′ and 5′-GCCGTCGACATGCAACAACGCATT-
GACAG-3′. Both PCR products were cloned into pCMV-SPORT6 vectors 
(Invitrogen) using restriction enzymes EcoRI and SalI following verification 
by sequence analysis. Subsequently, both the KCNA1 wild-type and N255D 
sequences were subcloned via the Gateway pDONR221 entry vector into a 
pCIneo IRES-GFP destination clone, creating human KCNA1 pCIneo IRES 
GFP (wild-type Kv1.1) and human KCNA1 N255D pCIneo IRES GFP (Kv1.1 
N255D). The pCIneo IRES GFP construct was used as a control (mock) in 
the experiments. The wild-type TRPM6 pCIneo IRES GFP construct has 
been described previously (6).
Electrophysiology. HEK293 cells were cultured and transfected as described 
previously (36). Whole-cell recordings were performed as described in a 
previous study (14). Recorded Kv1.1 currents were evoked as described 
previously, using the same standard pipette and bath solutions (37). The 
membrane potential of transfected HEK293 cells was measured using the 
current clamp mode, with continuous recording from a holding current 
of 0 pA. The pipette solution contained (in mM): 140 KCl, 1 Na2-ATP, 
10 HEPES/KOH (pH 7.3). The bath solution contained (in mmol/l): 
138 NaCl, 5.4 KCl, 1.2 MgCl2, 1 CaCl2, 10 glucose, and 10 HEPES/KOH 
(pH 7.3). For measurement of TRPM6-mediated currents, a linear voltage 
ramp from –100 to +100 mV (within 450 ms) was applied every 2 seconds 
research article
942	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 4   April 2009
from a holding potential of 0 mV. The standard pipette solution contained 
(in mmol/l): 150 NaCl, 10 EDTA, and 10 HEPES/KOH (pH 7.2). The extra-
cellular solutions contained 150 mmol/l NaCl, 10 mmol/l HEPES/KOH 
(pH 7.4). The analysis and display of patch clamp data were performed 
using IGOR Pro software (WaveMetrics). Current densities were obtained 
by normalizing the current amplitude to the cell membrane capacitance.
Cell surface biotinylation. HEK293 cells were transiently transfected using 
Lipofectamine 2000 (Invitrogen) with 1 μg DNA of wild-type Kv1.1, 1 μg 
Kv1.1 N255D, or 1 μg mock plasmid or cotransfected with 0.5 μg wild-
type Kv1.1 and 0.5 μg Kv1.1 N255D. Cell surface labeling with biotin was 
performed as described previously (38). At 48 hours after transfection, the 
biotinylation assay was performed. Cells were homogenized in 1 ml lysis 
buffer as described previously (38), using the Sulfo-NHS-LC-LC-Biotin 
(Pierce; Thermo Scientific). One percent of the total protein amount was 
collected as an input sample. Subsequently, biotinylated proteins (plasma 
membrane fraction) were precipitated using NeutrAvidin-agarose beads 
(Pierce; Thermo Scientific). Kv1.1 expression was analyzed by immunoblot 
analysis for the input and the plasma membrane fraction using the mono-
clonal Kv1.1 antibody (1:1,000).
Chemicals. The guinea pig antibody against AQP2 was provided by P.M. 
Deen (Radboud University Nijmegen Medical Centre). Mouse anti–calbin-
din D28K was purchased from Sigma-Aldrich. Rabbit polyclonal and mouse 
monoclonal antibodies specific for Kv1.1 were purchased from Alomone 
Labs and NeuroMab, for immunohistochemistry and Western blotting, 
respectively. DTX-K was purchased from Sigma-Aldrich.
Statistics. Data are shown as mean ± SEM. Statistical significance was 
determined using ANOVA with Tukey’s procedure. Differences in means 
with P < 0.05 were regarded as statistically significant. Statistical analysis 
was performed using Prism (GraphPad) software.
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